Who is sponsoring NCT00591188?

NCT00591188 is sponsored by Kidney Cancer Research Bureau.

What drugs are being tested in NCT00591188?

Interventions in NCT00591188: capecitabine, interferon-alpha.

What condition does NCT00591188 study?

NCT00591188 studies Carcinoma, Renal Cell.

Is NCT00591188 still recruiting?

NCT00591188 is currently completed. Last updated 30 April 2009.

Last reviewed 2009-04-30 · How we verify

NCT00591188

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Study of Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens

Completed Phase 2 Last updated 30 April 2009

What this trial tests

Phase 2 trial testing capecitabine, interferon-alpha in Carcinoma, Renal Cell in 49 participants. Completed.

Timeline

1 December 2006

Primary endpoint
1 May 2008

Quick facts

Lead sponsor	Kidney Cancer Research Bureau
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	49
Start date	1 December 2006
Primary completion	1 May 2008
Sites	1 location across Russia

Drugs / interventions tested

capecitabine, interferon-alpha — full drug profile →

Conditions studied

Carcinoma, Renal Cell — all drugs for Carcinoma, Renal Cell →

Sponsor

Kidney Cancer Research Bureau — full company profile →

Who can join

Adults 18 to 80, any sex, with Carcinoma, Renal Cell. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Evaluate progression-free survival with capecitabine and interferon treatment in metastatic renal cell carcinoma (MRCC) patients (pts) with IL-2 failure in first-line
Time frame: one year

Sponsor's own description

The aim of this study is to determine preliminary efficacy of capecitabine and interferon-alpha in second-line after interleukin-2 based regimens in patients with MRCC

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Carcinoma, Renal Cell

Currently open trials in the same condition.

NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT07227415 — Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica · Phase 1, PHASE2 · recruiting
NCT06222593 — Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant · Phase 1, PHASE2 · recruiting
NCT07166445 — Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT · recruiting
NCT06676527 — Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma · recruiting

Other Kidney Cancer Research Bureau trials

Trials by the same sponsor.

NCT07292168 — A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Ex · Phase 1, PHASE2 · recruiting
NCT05859477 — Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer · Phase 2 · unknown
NCT06648902 — Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated F · Phase 1, PHASE2 · completed
NCT04749602 — Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion. · Phase 2 · completed
NCT03379012 — Testosterone in Metastatic Renal Cell Carcinoma Patients · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00591188 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kidney Cancer Research Bureau
Last refreshed: 30 April 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00591188.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing